Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Gynecol Oncol. 2017 May 1;146(1):179–186. doi: 10.1016/j.ygyno.2017.04.023

Figure 2.

Figure 2

ADCC results (mean ± SD) of SYD985, T-DM1, Trastuzumab and ADC isotype control in a representative HER2 3+ expressing cell line (KRCH31, panel A), a representative 2+ HER2 expressing cell line [OVA5, panel B] and a representative 1+/0 HER2 expressing cell line (OVA3, panel C).